Employees face layoffs, but Congress confident on funding

Young, Jeffrey
August 2007
Hill;8/2/2007, Vol. 14 Issue 95, p22
The article reports that employees from the U.S. Food and Drug Administration (FDA) could face layoff notices in their inboxes this 2007. August 1 marked the deadline for the agency to warn pharmaceutical and medical-device reviewers and other employees that their jobs might be in jeopardy because legislation extending their funding, which expires September 30, has not been finalized.


Related Articles

  • The State Is at the Epicenter of Pharma Job Cuts. Gaudio, Thomas // njbiz;6/16/2008, Vol. 21 Issue 25, p23 

    The article reports on the industry-wide downsizing among pharmaceutical firms in New Jersey. The state stands in the epicenter of lay-offs as many pharmaceutical firms are based there or have a large presence. It cites the factors behind the downsizing which include the drug patent expirations...

  • Pharmacyclics Cuts Staff, Shifts Focus to Early Stage Candidates. Boggs, Jennifer // BioWorld Today;3/3/2008, Vol. 19 Issue 42, p1 

    The article reports on the restructuring of Pharmacyclics Inc. The Sunnyvale, California-based company decided to reduce its workforce by 40 percent. Pharmacyclics Inc. is also planning to refocus itself to drugs for cancer and immune-mediated diseases. The restructuring of the company follows a...

  • Layoffs At La Jolla. Allen, Mike // San Diego Business Journal;4/4/2005, Vol. 26 Issue 14, p37 

    The article reports that La Jolla Pharmaceutical Co. said it will cut its work force by about 60 positions, or 39 percent, after the U.S. Food and Drug Administration said the company's lupus treatment drug was not likely to receive accelerated approval. Shares of the company rose 2 cents on...

  • CDRH appropriations flat under House proposal. McCARTY, MARK // Medical Device Daily;6/7/2013, Vol. 17 Issue 110, p7 

    The article reports on the analysis made by the Alliance for a Stronger FDA on June 5, 2013, saying that a budget proposal for fiscal 2014 by the U.S. House Appropriations Committee would leave the Center for Devices and Radiological Health flat-funded compared to the amounts allowed for fiscal...

  • Point Therapeutics cuts workforce following failed trial.  // PharmaWatch: Cancer;Jul2007, Vol. 6 Issue 7, p19 

    The article reports that Point Therapeutics Inc. has terminated an estimated 60% of its staff to reduce costs after discontinuing its phase III trials for talabostat, a cancer drug used to treat non-small cell lung cancer. According to the author, the company will be spending approximately $130,...

  • GPC Eliminates 46 Positions In New Round Of Job Cuts. Sheridan, Cormac // BioWorld International;8/29/2007, Vol. 12 Issue 35, p1 

    The article reports on the decision of GPC Biotech AG to eliminate 46 jobs at its Princeton, New Jersey site, which represents approximately 15 percent of its payroll. The decision was prompted after its failure to obtain accelerated approval from the U.S. Food and Drug Administration (FDA) for...

  • Genta Cutting Staff, Selling Ganite in Wake of Rejection.  // BioWorld Today;4/3/2008, Vol. 19 Issue 65, p2 

    This article reports on the actions taken by Genta Inc. after the U.S. Food and Drug Administration requested for more trials for Genasense. The company decided to dismiss thirty-percent of the company's work force, and it even placed its only marketed product Ganite for sale. According to...

  • Genta Shares Soar as FDA Sets Genasense Action Date.  // BioWorld Today;7/15/2008, Vol. 19 Issue 136, p6 

    The article reports on the acceptance by the U.S. Food and Drug Administration (FDA) of an amendment to the drug application of Genta Inc. for Genasense in July 2008. Said amendment was in reaction to a March FDA rejection of Genta's appeal of a December 2006 approvable letter for Genasense. An...

  • Arpida, Introgen Restructure in Wake of Regulatory Setbacks. Morrison, Trista // BioWorld Today;12/2/2008, Vol. 19 Issue 233, p1 

    The article reports on the downsizing plans of Arpida AG and Introgen Therapeutics Inc. as a result of regulatory setbacks in the U.S. Switzerland-based Arpida will eliminate up to 60 jobs after its shares fell in November 2008 due to the decision by the U.S. Food and Drug Administration (FDA)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics